CVRx (CVRX)
Implantable Barostim therapy improves symptoms for eligible heart-failure patients.
$2.81
vs last close−0.08 (−2.94%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 57.54% | 15.33M shares | |
|---|---|---|---|
| 92 holders · as of Jun 30, 2026 | |||
| Insiders | 12.16% | 3.24M shares | |
| 15 holders · as of Aug 24, 2026 | |||
| Strategic holders | 6.42% | 1.71M shares | |
| 1 holder · as of Feb 6, 2025 | |||
| Other | 23.88% | 6.36M shares | |
| remainder | |||
26.64M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
92 holders · 15.33M shares · 10 new positions · 44 increased · 30 reduced · 18 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Johnson & Johnson | 4.02M | 15.11% | 0 | Aug 6, 2026 |
| Nea Management Company, LLC | 1.95M | 7.34% | −71.6K | Aug 14, 2026 |
| BlackRock, Inc. | 1.25M | 4.67% | +218.9K | Aug 7, 2026 |
| Royal Bank of Canada | 1.23M | 4.63% | +526.3K | Aug 14, 2026 |
| GSK PLC | 1.01M | 3.78% | 0 | Aug 13, 2026 |
| Vanguard Capital Management LLC | 910.6K | 3.42% | −734 | Aug 13, 2026 |
| Silvercrest Asset Management Group LLC | 878.1K | 3.30% | +306.1K | Aug 14, 2026 |
| Geode Capital Management, LLC | 440.8K | 1.65% | +13.7K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Johnson & Johnson | 15.40% | 4.02M | 13G | Jan 12, 2026 |
| NEA Partners 10, Limited Partnershipincl. New Enterprise Associates VIII, Limited Partnership, New Enterprise Associates 8A, Limited Partnership +5 more | 7.80% | 2.03M | 13D | Feb 20, 2025 |
| Vensana Capital I GP, LLC | 7.10% | 1.71M | 13G | Feb 6, 2025 |
| Chernett Jorey | 5.50% | 1.46M | 13D | Aug 24, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 13, 2026 | Brent Binkowskiofficer: CHIEF OPERATING OFFICER | Purchase | 26,223 | $2.91 | 56,514 |
| Aug 12, 2026 | Brent Binkowskiofficer: CHIEF OPERATING OFFICER | Sale | 1,309 | $2.55 | 30,291 |
| Mar 2, 2026 | Philip B. Adamsonofficer: Chief Medical Officer | Sale | 1,262 | $7.90 | 61,578 |
| Mar 2, 2026 | Robert Allen Johnofficer: Chief Revenue Officer | Sale | 3,964 | $7.90 | 86,036 |
| Mar 2, 2026 | Jared Oasheimofficer: CHIEF FINANCIAL OFFICER | Sale | 1,744 | $7.90 | 96,703 |
| Mar 2, 2026 | Paul Verrastroofficer: CHIEF MKTG & STRAT OFFICER | Sale | 1,284 | $7.90 | 60,551 |
| Mar 2, 2026 | Kevin Hykesdirector, officer: PRES & CEO | Sale | 7,763 | $7.90 | 284,237 |
| Feb 20, 2026 | Mudit K. Jaindirector | Purchase | 46,800 | $6.36 | 980,183 |
| Feb 18, 2026 | Mudit K. Jaindirector | Purchase | 600 | $4.64 | 5,650 |
| Nov 26, 2025 | Johnson & Johnson10 percent owner | Sale | 6,337 | $10.03 | 4,024,861 |
House and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Sen. Richard Blumenthal · CT | Sale | $1,001 – $15,000 | Spouse | Jul 8, 2026 | Aug 26, 2026 |